Antipain inhibits N-methyl-N'-nitro-N-nitrosoguanidine-induced transformation and increases chromosomal aberrations.
The morphologic transformation induced in Syrian hamster embryo cells by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (0.25 microgram/ml of medium) is inhibited by posttreatment with antipain (6-600 microgram/ml), a protease inhibitor, but is unaffected by pretreatment. DNA replication relative to untreated controls is not affected by MNNG, antipain, or the combination of the two; no synergistic lethality of antipain and MNNG occurred as reflected in the cloning efficiency. Antipain was ineffective in influencing MNNG-induced sister chromatid exchanges, but it increased frequencies of chromosomal aberration (per metaphase) at 10, 26, and 40 hr when cells were treated with MNNG at 0.25 microgram/ml of medium followed by antipain 10 min later, the procedure used in the transformation studies. Antipain also increased the average number of aberrations at the second mitosis (34 hr) when the MNNG concentration was doubled. Chromatid exchanges increased 26 hr posttreatment with the combination of MNNG and antipain used for transformation. No difference in MNNG-induced aberrations was observed when antipain preceded MNNG by 24 hr. Although the mode of actin of antipain is unknown, antipain does not inhibit transformation by suppressing chromosomal rearrangements that could convert recessive mutations to the homozygous state.
D000818:Animals; D000976:Antipain / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002869:Chromosome Aberrations; D006224:Cricetinae; D004261:DNA Replication / Q000187:drug effects; D008677:Metaphase; D008769:Methylnitronitrosoguanidine / Q000037:antagonists & inhibitors*; D009842:Oligopeptides / Q000494:pharmacology*; D012854:Sister Chromatid Exchange / Q000187:drug effects
D009842:Oligopeptides; D008769:Methylnitronitrosoguanidine; D000976:Antipain